Skip to main content
S 4472 119th Congress Senate Health Department of Health and Human Services Drug therapy Food and Drug Administration (FDA) Government information and archives Health programs administration and funding Internet, web applications, social media Medical research National Institutes of Health (NIH) Neurological disorders Public-private cooperation Research administration and funding

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Introduced: April 30, 2026 Introduced by: Murkowski, Lisa Republican · Alaska See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 10 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Aug 10, 2026
Held at the desk.
Aug 10, 2026
Received in the House.
Aug 10, 2026
Message on Senate action sent to the House.
Aug 4, 2026
Passed Senate with an amendment by Voice Vote. (consideration: CR S4425-4426; text: CR S4425-4426)
Aug 4, 2026
Passed/agreed to in Senate: Passed Senate with an amendment by Voice Vote.
Jul 16, 2026
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
Jul 16, 2026
Placed on Senate Legislative Calendar under General Orders. Calendar No. 461.
Jun 17, 2026
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Apr 30, 2026
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Apr 30, 2026
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.

The bill reauthorizes

  • grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
  • grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
  • a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. 

Also, the bill revises the NIH grants to require (1) the NIH, in considering grant renewal, to assess available information on the safety and efficacy of the investigational drugs; (2) grantees to promptly report available safety data from ongoing clinical trials; and (3) the NIH to determine the timeframe for enrollment in clinical trials for the investigational drugs.

Additionally, every five years, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, for ALS and other rare neurodegenerative diseases. Each plan must include the FDA's previous actions and recommendations for improvements.

Finally, the Government Accountability Office and the Department of Health and Human Services must report on the impacts of these grants. 

What's happening now August 10, 2026

Held at the desk.

 Hearings & markups 1
 Related & companion bills 1
  • HR 8205 Related bill Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
 Bill text 3 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 3

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

 Cosponsors 15
All 15 Democratic 8 Republican 7
R
Barrasso, John
Wyoming · Jul 23, 2026
 D
Whitehouse, Sheldon
Rhode Island · Jul 23, 2026
 R
McCormick, David
Pennsylvania · Jul 21, 2026
 D
Merkley, Jeff
Oregon · Jul 21, 2026
 R
Daines, Steve
Montana · Jun 24, 2026
 D
Markey, Edward J.
Massachusetts · Jun 24, 2026
 R
Banks, Jim
Indiana · Jun 16, 2026
 R
Curtis, John R.
Utah · Jun 16, 2026
 D
Gillibrand, Kirsten E.
New York · Jun 16, 2026
 D
Hassan, Margaret Wood
New Hampshire · Jun 16, 2026
 R
Capito, Shelley Moore
West Virginia · Jun 15, 2026
 R
Collins, Susan M.
Maine · Jun 15, 2026
 D
Klobuchar, Amy
Minnesota · Jun 15, 2026
 D
Padilla, Alex
California · Jun 15, 2026
 D
Coons, Christopher A.
Delaware · Apr 30, 2026
Cite this page click to expand
APA
U.S. Congress. (2026). S. 4472: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026. 119th Congress. Open America. https://openamerica.io/bill/119-S-4472/
MLA
"S. 4472: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-S-4472/.
Bluebook (legal)
S. 4472, 119th Cong. (2026), https://openamerica.io/bill/119-S-4472/.
Markdown link
[S. 4472: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026](https://openamerica.io/bill/119-S-4472/)
Report a problem